Literature DB >> 15950935

Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.

Xiong Zhang1, Wenjie Xie, Shen Qu, Tianhong Pan, Xiaotong Wang, Weidong Le.   

Abstract

The cause of the neurodegenerative process in Parkinson's disease (PD) remains unclear, but evidence suggests that failure of the ubiquitin-proteasome system may play a major role in the pathogenesis of the disease. Iron is believed to be a key contributor to PD pathology by inducing aggregation of alpha-synuclein and by generating oxidative stress. Our present studies have shown that micro-injection of the proteasome inhibitor lactacystin into the substantia nigra (SN) of C57BL/6 mice causes significant loss of dopaminergic cells and induces intracellular inclusion body formation. We have also found that co-injection of the iron chelator desferrioxamine not only attenuates the lactacystin-induced dopamine neuron loss, but also reduces the presence of ubiquitin-positive intracellular inclusions in the SN, whereas use of iron-deficient diet has no such protective effects. These results may support that iron plays a key role in proteasome inhibitor-induced nigral pathology and that reducing iron reactivity may prevent dopaminergic neuron degeneration and reduce abnormal protein aggregation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950935     DOI: 10.1016/j.bbrc.2005.05.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

Review 1.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 2.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

3.  Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.

Authors:  Shannon L Rhodes; Daniel D Buchanan; Ismaïl Ahmed; Kent D Taylor; Marie-Anne Loriot; Janet S Sinsheimer; Jeff M Bronstein; Alexis Elbaz; George D Mellick; Jerome I Rotter; Beate Ritz
Journal:  Neurobiol Dis       Date:  2013-10-08       Impact factor: 5.996

4.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Authors:  Balaram Ghosh; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

Review 5.  Iron chelation and neuroprotection in neurodegenerative diseases.

Authors:  Xuping Li; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

6.  Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.

Authors:  Patcharee Kooncumchoo; Sushil Sharma; James Porter; Piyarat Govitrapong; Manuchir Ebadi
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  Adaptive changes in autophagy after UPS impairment in Parkinson's disease.

Authors:  Yu-fei Shen; Yu Tang; Xiao-jie Zhang; Kai-xing Huang; Wei-dong Le
Journal:  Acta Pharmacol Sin       Date:  2013-03-18       Impact factor: 6.150

Review 8.  Brain Iron Metabolism Dysfunction in Parkinson's Disease.

Authors:  Hong Jiang; Jun Wang; Jack Rogers; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.